



To: Participating Physicians and Healthcare Providers

From: Geralyn Lambert-Messerlian, PhD
Director, CNE Clinical Chemistry and Special Testing

Diane Panizza, MT(ASCP)
Manager, Special Testing Lab

C. James Sung, MD
Executive Chief of Pathology and Laboratory Medicine, Care New England

Date: May 16, 2022

RE: **Autoimmune antibody testing**

Autoimmune antibody testing is available in-house by an ELISA method on the Thermo Fisher Phadia™ system for Care New England providers, **effective May 18**. Results are expressed as positive, negative or equivocal for the presence of autoantibodies, with repeat testing indicated in the latter case.

The celiac disease screen will be performed by examining antibodies against tissue transglutaminase (TTG IgA and IgG Antibody) and gliadin (IgA and IgG Deamidated). Per recommended algorithms, equivocal results for TTG IgA will be reflexed to endomysial send-out antibody testing.

The phospholipid antibody screen consists of testing for the presence of antibodies against cardiolipin (IgG, IgM and IgA) and beta-2-glycoprotein (IgG, IgM and IgA).

Lastly, screening for connective tissue disease is performed for an anti-nuclear antibody panel including dsDNA (ANA screen with ENA reflex). Patients who are screen positive will be reflexed to individual ENA tests, including Smith, SS-A/Ro, SS-B/La, Jo-1, Scl-70, U1 RNP and RNP 70. The ENA tests may also be ordered individually.

For indications where morphological characterization and/or a titer of anti-nuclear antibodies is required or preferred, Anti-Nuclear Antibody HEP-2 (ANAIFA) remains an option through send-out testing.

Please direct questions to the Special Chemistry Lab at 401-453-7650.



(401) 227-3669



4 Richmond Square
Providence, RI 02906



www.carenewengland.org